

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

Proposed Multiple Technology Appraisal (MTA)

Alemtuzumab, dimethyl fumarate, laquinimod and teriflunomide for the treatment of relapsing forms of multiple sclerosis

Provisional matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Manufacturers/sponsors</u></p> <ul style="list-style-type: none"> • Biogen Idec (dimethyl fumarate) • Genzyme, a Sanofi company (alemtuzumab) • Sanofi (teriflunomide) • Teva Pharmaceuticals (laquinimod) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • Afiya Trust • Black Health Agency • Brain and Spine Foundation • Counsel and Care • Disability Rights UK • Equalities National Council • Leonard Cheshire Disability • Multiple Sclerosis National Therapy Centres • Multiple Sclerosis Resource Centre • Multiple Sclerosis Society • Multiple Sclerosis Trust • Muslim Council of Britain • Muslim Health Network • South Asian Health Foundation • Specialised Healthcare Alliance • Sue Ryder Care <p><u>Professional groups</u></p> <ul style="list-style-type: none"> • Association of British Neurologists • British Association for Services to the Elderly • British Geriatrics Society • British Neuropathological Society • British Society of Rehabilitative Medicine 	<p><u>General</u></p> <ul style="list-style-type: none"> • Allied Health Professionals Federation • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Commissioning Support Appraisals Service • Department of Health, Social Services and Public Safety for Northern Ireland • Healthcare Improvement Scotland • Medicines and Healthcare products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • NHS Alliance • NHS Commercial Medicines Unit • NHS Confederation • Public Health Wales NHS Trust • Scottish Medicines Consortium • Wales Neurological Alliance <p><u>Possible comparator manufacturer(s)</u></p> <ul style="list-style-type: none"> • Alkermes Inc (natalizumab) • Bayer (interferon beta-1b) • Biogen Idec (interferon beta-1a, natalizumab) • Merck Serono (interferon beta-1a) • Novartis Pharmaceuticals UK (fingolimod, interferon beta-1b) • Sanofi (glatiramer acetate) • Teva Pharmaceuticals (glatiramer acetate)

National Institute for Health and Clinical Excellence
 Provisional matrix for the proposed technology appraisal alemtuzumab, dimethyl fumarate, laquinimod and teriflunomide for the treatment of relapsing forms of multiple sclerosis

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> • Chartered Society of Physiotherapy • College of Occupational Therapists • Institute of Neurology • Neurological Alliance • Neurosupport • Primary Care Neurology Society • Royal College of General Practitioners • Royal College of Nursing • Royal College of Pathologists • Royal College of Physicians • Royal Pharmaceutical Society • Royal Society of Medicine • Therapists in MS (TIMS) • United Kingdom Clinical Pharmacy Association • United Kingdom Multiple Sclerosis Specialist Nurse Association (UKMSSNA) <p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health • Norfolk and Great Yarmouth & Waveney PCT Cluster • Outer North East London PCT Cluster • Welsh Government 	<p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • Brain Research Trust • Cochrane Multiple Sclerosis Group • MRC Clinical Trials Unit • National Institute for Health Research • Research Institute for the Care of Older People <p><u>Assessment Group</u></p> <ul style="list-style-type: none"> • Assessment Group tbc • National Institute for Health Research Health Technology Assessment Programme <p><u>Associated Guideline Groups</u></p> <ul style="list-style-type: none"> • National Clinical Guideline Centre <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> • tbc

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Government and relevant NHS organisations in England.

Consultees can participate in the consultation on the draft scope, the Assessment Report and the Appraisal Consultation Document, they are invited to prepare a submission dossier and all non-manufacturers/sponsors consultee organisations can nominate clinical specialists and patient experts to present their personal views to the Appraisal Committee. All consultees are given the opportunity to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare a submission dossier, and that receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; NHS Quality Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, and the *British National Formulary*).

All non-manufacturers/sponsors commentator organisations can nominate clinical specialists and patient experts to present their personal views to the Appraisal Committee.

Assessment Group

An independent academic group (commissioned by the National Institute for Health Research (NIHR) Health Technology Assessment Programme (HTA Programme) to assist in the appraisal) prepares an Assessment Report on the health technology (a review of the clinical and cost effectiveness of the technology(ies) based on a systematic review of the literature and a review of manufacturer and sponsor submission to the Institute).